Viewing Study NCT01426334


Ignite Creation Date: 2025-12-25 @ 2:25 AM
Ignite Modification Date: 2026-03-11 @ 10:28 PM
Study NCT ID: NCT01426334
Status: TERMINATED
Last Update Posted: 2014-04-02
First Post: 2011-08-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
Sponsor: National Cancer Institute (NCI)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Accelerated Phase Chronic Myelogenous Leukemia View
None Chronic Myelogenous Leukemia, BCR-ABL1 Positive View
None Chronic Phase Chronic Myelogenous Leukemia View
None Relapsing Chronic Myelogenous Leukemia View
Keywords: